Naveris has developed highly sensitive blood tests for cancers to enable early diagnosis in the general asymptomatic population, real-time monitoring of response in patients undergoing treatment, and detection of cancer recurrence in patients in remission.
Our tests use disruptive proprietary technology to capture and analyze cancer-associated DNA in blood plasma that has increased sensitivity compared to existing circulating tumor DNA tests.
Our flagship technology is NavDx®, a liquid biopsy test that analyzes tumor-tissue-modified DNA in the blood to detect Human papillomavirus (HPV)-related cancer. In clinical studies, NavDx® has established its ability to monitor head & neck cancer recurrence.¹˒²˒³ A positive blood test preceded the detection of recurrence by imaging for 91% of patients, with a median lead-time of 3.9 months.¹
